Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?
Jeremias
Allen
A
Division of Cardiovascular Medicine, Department of Medicine, Stony Brook University Health Sciences Center T 16-080, Stony Brook, NY 11794-8171, USA. allen.jeremias@stonybrook.edu
Gruberg
Luis
L
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004617:Embolism / Q000517:prevention & control*; D000077542:Eptifibatide; D006470:Hemorrhage / Q000139:chemically induced; D006629:Hirudins; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000517:prevention & control*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D006629:Hirudins; D007140:Immunoglobulin Fab Fragments; D010446:Peptide Fragments; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D000077542:Eptifibatide; C074619:bivalirudin; D000077284:Abciximab